Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION RECEIVES CANADIAN REGULATORY APPROVAL FOR AGRELIN(R) TREATMENT IND

 EATONTOWN, N.J., Feb. 2 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ-NMS: RPCX) announced today that the Canadian Health Protection Branch (HPB) has approved a Treatment IND for Agrelin(R) (anagrelide) capsules, permitting the firm to sell the drug product without promotion for the indication of thrombocytosis. Thrombocytosis is a serious clinical disorder caused by the presence of excessive numbers of blood platelets in the peripheral circulation. Blood platelets are the body's first line of defense against bleeding, and a normal blood clotting mechanism is established when the blood platelet count is in the normal range. When elevated, however, a high platelet count is often accompanied by excessive clotting, resulting in among other things, heart attacks and stroke. Agrelin reduces the elevated platelet counts of patients with thrombocytosis by slowing the rate of platelet production by the bone marrow. Agrelin is not intended for use in patients with normal blood platelet levels.
 "We are pleased that HPB considers Agrelin to be an important new drug", stated Dr. Robert A. Vukovich, Roberts president and CEO. "This Treatment IND will permit patients expanded access to Agrelin during the period preceding NDS approval," he continued. Roberts Canadian subsidiary, Roberts Pharmaceuticals of Canada, Inc. will be responsible for handling the distribution of Agrelin. Roberts submitted a New Drug Application (NDA) to the FDA in December.
 Roberts Pharmaceutical is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the U.S., Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 -0- 2/2/93
 /CONTACT: Anthony Maris of Roberts Pharmaceutical Corporation, 908-389-1182/
 (RPCX)


CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU:

TM-KW -- NY002 -- 1755 02/02/93 10:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 2, 1993
Words:331
Previous Article:CABOT OIL & GAS CORPORATION REPORTS INCREASED EARNINGS
Next Article:METLIFE AND START EXPAND RELATIONSHIP TO HELP CONSUMERS SAVE FOR THEIR FUTURE
Topics:


Related Articles
ROBERTS ANNOUNCES CLINICAL TRIAL RESULTS FOR AGRELIN IN THROMBOCYTOSIS
ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS WITH DRUG FOR PROSTATE CANCER
ROBERTS PHARMACEUTICAL CORPORATION FILES NEW DRUG APPLICATION FOR AGRELIN WITH FDA
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES UK APPROVAL FOR SOMAGARD
ROBERTS PHARMACEUTICAL SUBMITS NEW DRUG APPLICATION TO FDA FOR URINARY INCONTINENCE DRUG
ROBERTS PHARMACEUTICAL CORPORATION DRUG TO RECEIVE HIGH-PRIORITY EC REGULATORY REVIEW
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES ITS AGRELIN NEW DRUG APPLICATION HAS BEEN ACCEPTED FOR FILING BY FDA
ROBERTS PHARMACEUTICAL CORPORATION AND FDA TO MEET TO DISCUSS ACCELERATED APPROVAL OF PROAMATINE
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES FDA TO APPROVE THE COMPANY'S FIRST PIPELINE DRUG, PROAMATINE, UNDER THE ACCELERATED PROCESS
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES APPROVABLE LETTER AND PREPARES FOR U.S. LAUNCH OF PROAMATINE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters